From the Editor
  • Ajay Piramal started out in his family's textile business at age 22 in 1977 but went on to build a pharma empire through acquisitions.
  • Piramal inked his biggest deal in 2010 when he sold his domestic formulations business to Abbott Labs for $3.8 billion.
  • In 2020, Piramal sold his glass manufacturer Piramal Glass to private equity firm Blackstone for $1 billion.
  • In 2022, Piramal demerged the pharma and financial services businesses of his flagship Piramal Enterprises. Piramal Pharma was listed in October 2022.
  • Piramal's wife Swati is vice chairperson, while his daughter Nandini and son Anand have board seats.
Wealth History
HOVER TO REVEAL NET WORTH BY YEAR
Personal Stats
Age
70
Source of Wealth
Pharmaceuticals
Residence
Mumbai, India
Citizenship
India
Marital Status
Married
Children
2
Education
Bachelor of Arts/Science, University of Mumbai; Master of Business Administration, University of Mumbai
Did you know
Piramal is a non-executive director of Tata Sons, the holding outfit of Indian conglomerate Tata Group.
His son Anand got married to Mukesh Ambani's daughter, Isha, in December 2018. The wedding cost an estimated $100 million.
Piramal Alternatives, Piramal Group's fund management business, invested 2.5 billion rupees in electric bus maker, PMI Electro Mobility Solutions, in October 2023.
In Their Own Words

If it happens, it's good; but if it didn't happen, it's still good.

Ajay Piramal
Related People & Companies
Dilip Shanghvi & family
Dilip Shanghvi & family
Related by origin of wealth: Pharmaceuticals
View Profile
Setiawan family
Setiawan family
Related by origin of wealth: Pharmaceuticals
View Profile
India
India
Citizen of India
View Profile
Zhong Huijuan
Zhong Huijuan
Related by origin of wealth: Pharmaceuticals
View Profile
Pankaj Patel
Pankaj Patel
Related by origin of wealth: Pharmaceuticals
View Profile
Sun Piaoyang
Sun Piaoyang
Related by origin of wealth: Pharmaceuticals
View Profile

More on Forbes

Oct 1, 2010

The Next Act

Flush with cash from selling a chunk of his pharma business, Ajay Piramal faces a nice challenge: what to do with nearly $4 billion.